You are here

Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Member of the Ingenix Normative Health Informatics (NHI) Database during 01/01/2003
through 12/31/2007

- 18 years of age or older

- Had at least 183 days of continuous enrollment in the database

- No doctor visits associated with a diagnosis of ischemic optic neuropathy during the
183 days prior to cohort entry

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Less than 18 years of age

- Less than 183 days of continuous enrollment in the database

- At least one doctor visit associated with a diagnosis of ischemic optic neuropathy
during the 183 days prior to cohort entry

NCT01260324
Pfizer
Completed
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Transthyretin Familial Amyloid Poluneuropathy
NCT02146378
All Genders
Optic Nerve Diseases
NCT00359632
All Genders
18+
Years
Multiple Sites
Painful Diabetic Neuropathy
NCT00159679
All Genders
18+
Years
Multiple Sites
Chemotherapy-Induced Peripheral Neuropathy
NCT00380874
All Genders
18+
Years
Multiple Sites
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The Detection and Epidemiology of NAION in a Commercially Insured Population in the United States.
The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.

The study population consisted of members of the Ingenix Normative Health Informatics (NHI) Database during 01/01/2003 through 12/31/2007, who were 18 years of age or older with at least 183 days of continuous enrollment in the database and without any doctor visits associated with a diagnosis of ischemic optic neuropathy during the 183 days prior to cohort entry.

From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283).

From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)

Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
The study population consisted of members of the Ingenix Normative Health Informatics (NHI) Database during 01/01/2003 through 12/31/2007, who were 18 years of age or older with at least 183 days of continuous enrollment in the database and without any doctor visits associated with a diagnosis of ischemic optic neuropathy during the 183 days prior to cohort entry.
  • Anterior Ischemic Optic Neuropathy
  • Ischemic Optic Neuropathy
Other: No intervention given in this observational study
No intervention given in this observational study
  • NAION cases
    From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
    Intervention: Other: No intervention given in this observational study
  • Controls
    From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
    Intervention: Other: No intervention given in this observational study
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21283
March 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Member of the Ingenix Normative Health Informatics (NHI) Database during 01/01/2003 through 12/31/2007
  • 18 years of age or older
  • Had at least 183 days of continuous enrollment in the database
  • No doctor visits associated with a diagnosis of ischemic optic neuropathy during the 183 days prior to cohort entry

Exclusion Criteria:

  • Less than 18 years of age
  • Less than 183 days of continuous enrollment in the database
  • At least one doctor visit associated with a diagnosis of ischemic optic neuropathy during the 183 days prior to cohort entry
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01260324
A1481282
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now